2011/09/15 by Jaroslaw Czekaj, Aurélien Dinh, Andreea Moldovan +7
Medicine · #Antimicrobial Resistance in Staphylococcus #Infectious Diseases and Tuberculosis #Orthopedic Infections and Treatments
paper · doi:10.3109/00365548.2011.608082
crossref issued 2011/09/15 · crossref published 2011/09/15 · crossref published-online 2011/09/15 · openalex publication_date 2011/09/15 · crossref created 2011/09/15 · crossref published-print 2011/12/01 · crossref deposited 2023/06/09 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01 · crossref indexed 2026/08/01
A majority of osteoarticular and implant-related infections are due to staphylococci and biofilm formation. Combined therapy including rifampicin is frequently recommended. Indeed, rifampicin penetrates biofilms and kills adherent staphylococci, but cannot be administered as monotherapy because of the rapid emergence of resistant mutants. While several antibiotic combinations including rifampicin have been implemented, evaluation of the clindamycin-rifampicin combination has been neglected, presumably because of the emergence of alternative combinations, such as quinolone-rifampicin, and the fear of potential antagonistic interactions. We report a limited series of 20 patients (3 immune-suppressed) with 6 arthroplasty infections, 4 other implant infections, 7 native arthritis, and 3 osteomyelitis, who were all successfully treated with this oral combination for >75% of the antibiotic course (median duration 45 days). The excellent outcomes obtained with this antimicrobial combination after a mean follow-up of 2.6 y (range 1.0-6.1 y) warrant further clinical and microbiological studies for implementing this regimen in routine practice.